• SEQUENTIAL

  Participated · Equity · Mar 2026

  Sequential operates a proprietary non-invasive testing platform that integrates microbial and molecular analyses to quantify how ingredients and consumer, biotech, and pharmaceutical products alter skin biomarkers. The company has amassed one of the industry’s largest clinical datasets with over 50,000 samples, 4,000+ ingredients tested, and 10,000+ participants worldwide. Sequential runs labs in Cambridge, New York City and Singapore and has received support from Innovate UK, Enterprise Singapore and A*STAR among others. Following its $3.5M first equity round, bringing total dilutive and non-dilutive funding to $7.5M, the company plans to build an AI-driven discovery engine to predict, optimize and discover next‑generation active complexes and bioactive ingredients. Sequential is also expanding its biomarker discovery programs and global partnerships to commercialize scientifically validated ingredient complexes.

No current team members are available.